RT Journal Article
SR Electronic
T1 Cognitive subgroups of affective and non-affective psychosis show differences in medication and cortico-subcortical brain networks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.03.22278370
DO 10.1101/2022.08.03.22278370
A1 Katharina M Bracher
A1 Afra Wohlschläger
A1 Kathrin Koch
A1 Franziska Knolle
YR 2024
UL http://medrxiv.org/content/early/2024/02/12/2022.08.03.22278370.abstract
AB Cognitive deficits are prevalent in individuals with psychosis and are associated with neurobiological changes, potentially serving as an endophenotype for psychosis. Using the HCP Early Psychosis dataset (n=226), we aimed to replicate cognitive subtypes (deficit, intermediate, spared) through data-driven clustering on affective and non-affective psychosis patients and controls. We explored differences between the clusters in symptom manifestation, cognition, medication, and grey matter volume, comparing patients to controls. Fuzzy K-Means clustering on PCA-selected features revealed three cognitive subgroups significantly varying in clinical symptoms and cognitive impair-ment, and importantly also in medication and grey matter volume in fronto-parietal and subcortical networks. The spared cluster (86% controls, 37% affective psychosis, 17% non-affective psychosis) exhibited unimpaired cognition, lowest symptoms/medication, and grey matter comparable to controls. The deficit cluster (4% controls, 10% affec-tive psychosis, 47% non-affective psychosis) had impairments across domains, highest symptoms/medication, and pronounced grey matter alterations. The intermediate clus-ter (11% controls, 54% affective psychosis, 36% non-affective psychosis) showed fewer deficits than the second cluster, but similar symptoms/medication/grey matter to the first. Controlling for medication, cognitive scores correlated with grey matter changes and negative symptoms across all patients. Our findings generally emphasize the inter-play between cognition, brain structure, symptoms, and medication, and specifically suggest a possible mediating role of cognition linking alterations in brain structure and symptoms, which highlights the potential of screening cognitive changes to aid in tailoring treatments and interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFK received funding from the European Unions Horizon 2020 [Grant number 754462].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://www.humanconnectome.org/study/human-connectome-project-for-early-psychosisI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors